About Daphne Karydas
Daphne Karydas is a director at Mineralys Therapeutics.
Form D filings name Daphne Karydas as a director at Epikast.
Daphne Karydas reports to the SEC as a director or officer of 5 public companies, including COMPASS Pathways plc (CMPS), LogicBio Therapeutics (LOGC) and Syndax Pharmaceuticals (SNDX).
Daphne Karydas first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Daphne Karydas in the role, so the role may have started earlier or lasted longer.
MI
Mineralys Therapeutics, Inc.
Director
2023 – 2026 · Public company (MLYS)
CP
COMPASS Pathways plc
Director
2023 – 2026 · Public company (CMPS)
LI
LogicBio Therapeutics, Inc.
Director
2020 – 2022 · Public company (LOGC)
SI
Syndax Pharmaceuticals Inc
Chief Financial Officer
2020 – 2021 · Public company (SNDX)
EC
Eucrates Biomedical Acquisition Corp.
Director
2020 · Public company (EUCR)
Key Colleagues at Startups
The people Daphne Karydas works with at each company, as listed on that company's latest Form D.
Epikast Inc. · Form D, Feb 5, 2026
BP
Brad Prosek
Director
EV
Evangelos Vergetis
President and director
ON
Oleg Nodelman
Director
SP
Stelios Papadopoulos
Director
AT
Alexandros Tzoukas
Director
DP
Dimitrios Papalexopoulos
Director